CPRX Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of 16.9%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Corcept Therapeutics's return on equity of 23.78%.

Catalyst Pharmaceuticals has a consensus price target of $33.88, signalling upside risk potential of 53.63%. On the other hand Corcept Therapeutics has an analysts' consensus of $143.25 which suggests that it could grow by 108.76%. Given that Corcept Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.786, which suggesting that the stock is 21.371% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.145, suggesting its less volatile than the S&P 500 by 85.456%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Catalyst Pharmaceuticals's net income of $55.9M is higher than Corcept Therapeutics's net income of $30.7M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 16.83x while Corcept Therapeutics's PE ratio is 55.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.60x versus 11.54x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of 45.98%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Halozyme Therapeutics's return on equity of 162.37%.

Catalyst Pharmaceuticals has a consensus price target of $33.88, signalling upside risk potential of 53.63%. On the other hand Halozyme Therapeutics has an analysts' consensus of $67.75 which suggests that it could grow by 12.5%. Given that Catalyst Pharmaceuticals has higher upside potential than Halozyme Therapeutics, analysts believe Catalyst Pharmaceuticals is more attractive than Halozyme Therapeutics.

Catalyst Pharmaceuticals has a beta of 0.786, which suggesting that the stock is 21.371% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.323, suggesting its more volatile than the S&P 500 by 32.284%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are smaller than Halozyme Therapeutics quarterly revenues of $298M. Catalyst Pharmaceuticals's net income of $55.9M is lower than Halozyme Therapeutics's net income of $137M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 16.83x while Halozyme Therapeutics's PE ratio is 17.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.60x versus 7.67x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of -46.06%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Ionis Pharmaceuticals's return on equity of -103.27%.

Catalyst Pharmaceuticals has a consensus price target of $33.88, signalling upside risk potential of 53.63%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $57.43 which suggests that it could grow by 105.82%. Given that Ionis Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.786, which suggesting that the stock is 21.371% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.35%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $226.6M. Catalyst Pharmaceuticals's net income of $55.9M is higher than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 16.83x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.60x versus 5.92x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of 24.89%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Nektar Therapeutics's return on equity of -133.07%.

Catalyst Pharmaceuticals has a consensus price target of $33.88, signalling upside risk potential of 53.63%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 695.96%. Given that Nektar Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.786, which suggesting that the stock is 21.371% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are larger than Nektar Therapeutics quarterly revenues of $29.2M. Catalyst Pharmaceuticals's net income of $55.9M is higher than Nektar Therapeutics's net income of $7.3M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 16.83x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.60x versus 1.29x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.